Announcements Trials
Browse Landscape

Status

Withdrawn 1

Sponsor Class

OTHER 1

Study Type

Observational 1

Sponsor

Cancer Type

Lymphoid 1Dermatologic 1

Conditions

Lymphoma 37Leukemia, Lymphocytic, Chronic, B-Cell 30Lymphoma, Large B-Cell, Diffuse 25Multiple Myeloma 21Burkitt Lymphoma 21Lymphoma, Follicular 19Precursor Cell Lymphoblastic Leukemia-Lymphoma 18Lymphoma, Mantle-Cell 17Lymphoma, Non-Hodgkin 14Lymphoma, T-Cell 10Lymphoma, B-Cell, Marginal Zone 10Leukemia, Myeloid, Acute 10Myelodysplastic Syndromes 9Lymphoma, T-Cell, Cutaneous 9Lymphoma, B-Cell 9Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 8Mycosis Fungoides 8Leukemia, Biphenotypic, Acute 8Lymphoma, Large-Cell, Anaplastic 7Neuroectodermal Tumors, Primitive, Peripheral 5Neuroblastoma 5Leukemia, Myelomonocytic, Chronic 5Histiocytosis, Langerhans-Cell 5Glioma 5Wilms Tumor 4Waldenstrom Macroglobulinemia 4Sezary Syndrome 4Sarcoma 4Rhabdoid Tumor 4Medulloblastoma 4

Interventions

tofacitinib 5apremilast 1Lidocaine 1Etanercept 1Blood Specimen Collection 1Biopsy 1Aprepitant 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pruritus × Biopsy × Lymphoid × Clear all
NCT01801670 2015-01-27

Impact of Vorinostat on Pruritus Signaling Pathways - Merck Study

Boston University

Withdrawn
DermatologicLymphoid

Mycosis Fungoides, Pruritus, Lymphoma, T-Cell, Cutaneous

Data powered by HemOnc (CC BY 4.0) Colophon âš¡